Skip to content
Clinical Trials – home
NorwayBack to Norway

Clinical trials in Gjettum – page 49

616 clinical trials in Gjettum, Norway across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Gjettum at a glance
616
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

616 trials in Gjettum

Open in trial search

Study on the Safety and Effectiveness of Stereotactic Body Radiotherapy with or without Pembrolizumab for Patients with Unresected Stage I or II Non-Small Cell Lung Cancer

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Follicular lymphoma+2

Not recruiting

Study of Mosunetuzumab for Patients with Early Relapse of Follicular Lymphoma

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Mosunetuzumab
  • Sponsor:Oslo University Hospital HF

Neoplasm

Not recruiting

Study of Pembrolizumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study of Nivolumab, Ipilimumab, and UV1 Vaccine for Patients with Malignant Pleural Mesothelioma After Initial Chemotherapy

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Alrefimotide
  • Sponsor:Oslo University Hospital HF

Systemic mastocytosis

Not recruiting

Study on the Safety and Effectiveness of CGT9486 for Patients with Nonadvanced Systemic Mastocytosis

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bezuclastinib
  • Sponsor:Cogent Biosciences Inc.

Study on Physical Activity and Joint Health in Patients Aged 12 and Older with Severe Hemophilia A Treated with Efanesoctocog Alfa for 24 Months

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Efanesoctocog Alfa
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Study on the Safety and Effectiveness of Zilovertamab Vedotin for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Zilovertamab Vedotin
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer

Not recruiting

Study Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Pfizer Inc.

Malignant melanoma

Not recruiting

Study on Nivolumab for Preventing Melanoma Recurrence in Patients with Completely Removed Stage IIB/C Melanoma

Registered drug
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Hidradenitis

Not recruiting

Study to Evaluate the Effectiveness of Spesolimab for Patients with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of Pembrolizumab as Additional Treatment for Patients with Liver Cancer (Hepatocellular Carcinoma) After Surgery or Local Ablation

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Endometrial cancer

Not recruiting

Study of Navtemadlin as Maintenance Therapy for Patients with Advanced or Recurrent Endometrial Cancer After Chemotherapy

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Loperamide
  • Sponsor:Kartos Therapeutics Inc.

Other cities in Norway

The busiest research cities in the country

All 53 cities in Norway

Clinical research in Gjettum

What the registry says about research in the country

01 Gastroenterology Research

Innovative trials focusing on inflammatory bowel diseases, including studies of combination therapies for both Crohn's Disease and Ulcerative Colitis. Research aims to evaluate new treatment approaches using targeted biological agents.

  • Crohn's Disease Management
  • Ulcerative Colitis Treatment
  • Combination Therapy Assessment

These studies explore dual-therapy approaches to improve clinical outcomes for patients with moderate to severe disease activity.

02 Cardiovascular Studies

Research focusing on prevention and treatment of stroke and cardiac conditions, including innovative approaches for managing atrial fibrillation and evaluating new anticoagulation therapies.

  • Stroke Prevention
  • Atrial Fibrillation Management
  • Thrombolysis Research

Trials aim to improve outcomes in acute ischemic stroke and prevent cardiac complications.

03 Musculoskeletal Medicine

Comprehensive research into orthopedic conditions, including studies on osteoarthritis, carpal tunnel syndrome, and hip fracture treatments.

  • Joint Disease Management
  • Surgical vs. Conservative Treatment
  • Post-fracture Care

Investigations compare different treatment approaches and timing of interventions for optimal patient outcomes.

04 Infectious Disease Research

Studies addressing various infectious conditions including COVID-19 and mpox, evaluating novel therapeutic approaches and treatment strategies.

  • COVID-19 Treatment Trials
  • Mpox Management
  • Antiviral Therapy Assessment

Research focuses on understanding disease progression and testing new therapeutic interventions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.